Reach Us +44-1647-403003
Ichiei Narita | OMICS International
ISSN: 2165-7920

Journal of Clinical Case Reports
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Ichiei Narita


Recurrent Interstitial Lung Disease Induced By Various Therapies for Non-Small Cell Lung Cancer

Erlotinib is a human epidermal growth factor receptor type 1 tyrosine kinase inhibitor which is used for non-small cell lung cancer treatment. Interstitial lung disease has been reported as an adverse event of erlotinib. We report the case of a 39-year-old man with erlotinib-induced interstitial lung disease in a non-small cell lung cancer patient.... Read More»

Yu Saida, Satoshi Watanabe, Junko Baba, Jun Koshio, Rie Kondo, Masaaki Okajima, Satoru Miura, Tetsuya Abe, Hiroshi Tanaka, Junta Tanaka, Hiroshi Kagamu, Hirohisa Yoshizawa and Ichiei Narita

Case Report: J Clin Case Rep 2014, 4:471

DOI: 10.4172/2165-7920.1000471

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Relevant Topics